Part 6/Chapter 36/6-min read

Aortoiliac Occlusive Disease

Aortoiliac occlusive disease framed first as an inflow problem before the device decision: aortic bifurcation, common iliac, external iliac, and iliofemoral inflow placed inside the patient's symptom and risk profile. The chapter frames endovascular, hybrid, and open inflow reconstruction.

Edited by Tal M. Hörer MD, PhD · David T. McGreevy MD, PhD·Reviewed ·7 sections · 15 references

Listen to this chapter9 min · AI audio edition · two hostsAI narration

Multidisciplinary board: A board-room discussion with roles, escalation triggers, surveillance, patient goals, and what makes the pathway coherent.

General medical education, not patient-specific advice.

Choose the hosts

Definition and presentation

Aortoiliac occlusive disease is a limitation of arterial inflow caused by stenosis or occlusion of the aortic bifurcation, common iliac arteries, external iliac arteries, or the combined iliofemoral segment . Clinical presentation ranges across a spectrum of lower-extremity ischemia:

  • Asymptomatic peripheral artery disease.
  • Chronic symptomatic claudication, presenting as exertional disability.
  • Chronic limb-threatening ischemia (CLTI), presenting with rest pain, gangrene, or tissue loss.
  • Acute limb ischemia.

The disease occurs in isolation or as part of a multilevel pattern alongside femoropopliteal and infrapopliteal disease . Complete occlusion at the aortic bifurcation produces Leriche syndrome: the triad of bilateral buttock, thigh, or hip claudication, erectile dysfunction, and absent or diminished femoral pulses .

Classification and stratification

Aortoiliac morphology is stratified by the TASC II classification, which categorizes lesions A through D based on length, laterality, and involvement of the aortic bifurcation, common iliac, and external iliac arteries .

In CLTI, the aortoiliac segment is evaluated within the Global Vascular Guidelines framework, which stages disease using Patient risk, Limb severity, and ANatomic complexity (PLAN). Limb threat is stratified by the WIfI classification (Wound, Ischemia, foot Infection), and the target arterial path and expected limb-based patency are defined by the Global Anatomic Staging System (GLASS) . Aortoiliac repair in CLTI is evaluated as a component of this comprehensive limb strategy rather than as an isolated angiographic target.

Medical and antithrombotic therapy

Baseline medical management for aortoiliac disease includes blood-pressure control, statin therapy, smoking cessation, and structured exercise. Medical therapy is a prerequisite step in claudication and an ongoing requirement for secondary prevention across all disease stages .

Statin therapy is high-intensity: aortoiliac disease places the patient at very-high cardiovascular risk, so the LDL-C goal is below 1.4 mmol/L (below 55 mg/dL) with at least a 50% reduction from baseline . Cilostazol 100 mg twice daily improves pain-free walking distance and claudication symptoms and is the guideline-endorsed pharmacologic agent for symptom relief; it is contraindicated in heart failure of any severity .

For stable peripheral artery disease, rivaroxaban 2.5 mg twice daily plus aspirin reduces major cardiovascular events and major adverse limb events compared with aspirin alone, but increases the risk of major bleeding . Following lower-extremity revascularization, the same low-dose rivaroxaban and aspirin regimen reduces composite ischemic limb and cardiovascular events, with an associated increase in major bleeding . The antithrombotic regimen is individualized based on patient age, renal function, bleeding risk, and concomitant therapy.

Revascularization thresholds and treatment decision

The threshold for intervention is dictated by the clinical goal and the patient's presentation. In claudication, the threshold is qualitative: intervention is reserved for persistent, patient-defined disability after guideline-directed medical therapy and structured exercise have failed to provide functional improvement . In CLTI, the threshold is lower because the endpoint is limb salvage and wound healing; inflow correction is judged by whether it enables tissue repair or adequately supports a required distal reconstruction .

Treatment selection follows a stepwise anatomic and risk assessment:

  1. Decide whether inflow correction alone meets the clinical goal (relieving focal claudication) or whether it serves as a prerequisite for a distal target arterial path (CLTI).
  2. Attempt endovascular therapy for short, focal aortoiliac disease.
  3. Consider hybrid repair for concomitant iliac and common femoral disease.
  4. Reserve open reconstruction for extensive or heavily calcified disease in fit patients.
  5. Decline intervention in favor of observation or palliative care for prohibitive-risk patients or when life expectancy is severely limited.

Aortoiliac management and revascularization pathways

Stable claudication
  • Presentation or threshold
    Symptoms controlled or improving with exercise
    Preferred pathway
    Continued medical therapy and structured exercise
    Citation

  • Refractory claudication

    Presentation or threshold
    Persistent functional disability despite medical therapy and exercise
    Preferred pathway
    Revascularization matched to anatomy and risk
    Citation

  • CLTI

    Presentation or threshold
    Rest pain, gangrene, or tissue loss
    Preferred pathway
    Inflow correction as a primary or staged component of the limb plan
    Citation

  • Short, focal disease

    Presentation or threshold
    TASC A or B iliac stenosis or occlusion
    Preferred pathway
    Endovascular revascularization
    Citation

  • Concomitant iliofemoral disease

    Presentation or threshold
    Combined iliac inflow and common femoral disease
    Preferred pathway
    Hybrid repair (iliac stenting with open femoral reconstruction)
    Citation

  • Extensive aortoiliac disease

    Presentation or threshold
    TASC C or D disease, especially reaching renal arteries in fit patients
    Preferred pathway
    Open aortobifemoral bypass
    Citation

  • Prohibitive risk

    Presentation or threshold
    Limited life expectancy or prohibitive operative risk
    Preferred pathway
    No intervention or palliative wound care
    Citation

Endovascular and open techniques

Endovascular therapy is preferred for short iliac stenoses or occlusions when the clinical indication is established and anatomy is suitable . Device selection depends on lesion complexity. The COBEST trial demonstrated that covered balloon-expandable stents reduce binary restenosis compared with bare-metal stents overall; at 5-year follow-up, the durability advantage for covered stents persisted for extensive TASC C and D lesions, whereas outcomes for short TASC B lesions remained similar between covered and bare-metal platforms . Consequently, extensive disease justifies covered-stent selection, while focal lesions allow pragmatic platform choice.

Hybrid repair combines endovascular iliac inflow restoration with open femoral reconstruction. It is indicated when common femoral or iliofemoral disease restricts outflow, ensuring both a durable inflow channel and a usable femoral outflow bed .

Open aortobifemoral reconstruction is indicated for selected fit patients with extensive disease, particularly when occlusion reaches toward the renal arteries or when endovascular durability is insufficient for the patient's requirements . Aortobifemoral bypass carries primary patency of roughly 85% to 90% at 5 years and 70% to 75% at 10 years, with operative mortality near 3%. For complex bifurcation disease, open aortobifemoral bypass is evaluated against covered endovascular reconstruction of the aortic bifurcation (CERAB), kissing stents, and bifurcation stenting, with modality selection individualized by risk, calcification, and runoff .

Anatomic variants and calcification

Severe calcification restricts device selection and alters the threshold for declaring an endovascular approach suitable, as heavy calcification independently influences stent expansion and long-term durability .

When standard external iliac or common femoral outflow is occluded, deep femoral perfusion becomes critical. Profunda-dependent runoff requires the reconstruction to be planned around the profunda femoris arteries. Depending on extent, this may necessitate extending the reconstruction distally to include open aortoprofunda bypass if isolated iliac approaches are inadequate to establish durable inflow .

Areas of controversy

The optimal approach for complex aortic bifurcation occlusion remains unsettled. The relative superiority of open aortobifemoral bypass versus advanced endovascular techniques, including kissing stents and the CERAB technique, varies by institution, with decision-making driven heavily by local expertise, patient operative risk, and individual calcification patterns rather than definitive trial evidence . Furthermore, while covered stents improve patency in TASC C and D lesions, the exact anatomic threshold where open surgery definitively outperforms endovascular intervention for long-term durability continues to evolve alongside stent-graft technology .

References

  1. 1.
    2024 ACC/AHA Lower Extremity PAD Guideline (Gornik et al, JACC 2024).
    PubMed-indexed articleClinical practice guideline2024

    2024 ACC/AHA Lower Extremity PAD Guideline (Gornik et al, JACC 2024). doi:10.1016/j.jacc.2024.02.013.

    PubMedDOISource
  2. 2.
    Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007.
    DOI publisher routeClinical practice guideline2007

    Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007. doi:10.1016/j.jvs.2006.12.037.

    DOI
  3. 3.
    Global Vascular Guidelines on CLTI (Conte et al, J Vasc Surg 2019 / EJVES 2019).
    PubMed-indexed articleClinical practice guideline2019

    Global Vascular Guidelines on CLTI (Conte et al, J Vasc Surg 2019 / EJVES 2019). doi:10.1016/j.jvs.2019.02.016.

    PubMedDOISource
  4. 4.
    COMPASS PAD subgroup (Anand et al, Lancet 2018).
    PubMed-indexed articleRandomized controlled trial2018

    COMPASS PAD subgroup (Anand et al, Lancet 2018). doi:10.1016/S0140-6736(17)32409-1.

    PubMedDOISource
  5. 5.
    VOYAGER PAD (Bonaca et al, N Engl J Med 2020).
    PubMed-indexed articleRandomized controlled trial2020

    VOYAGER PAD (Bonaca et al, N Engl J Med 2020). doi:10.1056/NEJMoa2000052.

    PubMedDOISource
  6. 6.
    2024 ESC Guidelines for peripheral arterial and aortic diseases (Mazzolai et al, Eur Heart J 2024).
    PubMed-indexed articleClinical practice guideline2024

    2024 ESC Guidelines for peripheral arterial and aortic diseases (Mazzolai et al, Eur Heart J 2024). doi:10.1093/eurheartj/ehae179.

    PubMedDOISource
  7. 7.
    2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b. Eur Heart J. 2018.
    DOI publisher routeClinical practice guideline2017

    2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b. Eur Heart J. 2018. doi:10.1093/eurheartj/ehx095.

    DOI
  8. 8.
    COBEST trial (Mwipatayi et al, J Vasc Surg 2011).
    PubMed-indexed articleRandomized controlled trial2011

    COBEST trial (Mwipatayi et al, J Vasc Surg 2011). doi:10.1016/j.jvs.2011.06.097.

    PubMedDOISource
  9. 9.
    COBEST 5-year follow-up (Mwipatayi et al, J Vasc Surg 2016).
    PubMed-indexed articleRandomized controlled trial2016

    COBEST 5-year follow-up (Mwipatayi et al, J Vasc Surg 2016). doi:10.1016/j.jvs.2016.02.064.

    PubMedDOISource
  10. 10.
    ABF vs aortoiliac stenting with bifurcation reconstruction for TASC II D AIOD. Ann Vasc Surg. 2022;81:240-247.
    PubMed-indexed articleRegistry / cohort2022

    Comparison of Aortobifemoral Bypass to Aortoiliac Stenting with Bifurcation Reconstruction for TASC II D Aortoiliac Occlusive Disease. Ann Vasc Surg. 2022;81:240-247. PMID 34788703. DOI 10.1016/j.avsg.2021.10.040

    PubMedDOI
  11. 11.
    Indes JE, et al. ABF vs aortoiliac kissing stents in complex AIOD. J Vasc Surg. 2017;65(1):82-89.
    PubMed-indexed articleRegistry / cohort2017

    A comparison between aortobifemoral bypass and aortoiliac kissing stents in patients with complex aortoiliac obstructive disease. J Vasc Surg. 2017;65(1):82-89. PMID 27633164. DOI 10.1016/j.jvs.2016.06.107

    PubMedDOI
  12. 12.
    Aortobifemoral bypass vs covered endovascular reconstruction of the aortic bifurcation. J Vasc Surg. 2024.
    PubMed-indexed articleRegistry / cohort2024

    Aortobifemoral bypass vs covered endovascular reconstruction of the aortic bifurcation. J Vasc Surg. 2024. doi:10.1016/j.jvs.2024.03.437. PMID:38565344.

    PubMedDOI
  13. 13.
    CERAB SR Meta 2024.
    PubMed-indexed articleMeta-analysis / systematic review2024

    CERAB SR Meta 2024. doi:10.1016/j.jvs.2023.12.021. PMID:38104677.

    PubMedDOI
  14. 14.
    Aortoprofunda and internal iliac bypass in open repair of abdominal aortic aneurysm with aortoiliac occlusive disease. J Surg Case Rep. 2026.
    DOI publisher routeCase report2026

    Aortoprofunda and internal iliac bypass in open repair of abdominal aortic aneurysm with aortoiliac occlusive disease. J Surg Case Rep. 2026. doi:10.1093/jscr/rjaf1020.

    DOISource
  15. 15.
    Leriche R, Morel A. The syndrome of thrombotic obliteration of the aortic bifurcation. Ann Surg. 1948;127(2):193-206.
    PubMed-indexed article1948

    Leriche R, Morel A. The syndrome of thrombotic obliteration of the aortic bifurcation. Ann Surg. 1948;127(2):193-206. doi:10.1097/00000658-194802000-00001.

    PubMedDOI

Educational use only

AI assists this editorial workflow. Published updates are human-reviewed before publication.

Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.

Verify clinically relevant information against primary sources and current guidelines.

AI DisclosurePrivacyTermsCautions